TRICARE Expands Cancer Clinical Trials Demonstration

Publication
Article
OncologyONCOLOGY Vol 13 No 8
Volume 13
Issue 8

TRICARE, the health plan for active duty military personnel (formerly known as CHAMPUS), expanded its cancer clinical trials demonstration so that beneficiaries could enter cancer prevention trials sponsored by the National Cancer Institute

TRICARE, the health plan for active duty military personnel (formerly known as CHAMPUS), expanded its cancer clinical trials demonstration so that beneficiaries could enter cancer prevention trials sponsored by the National Cancer Institute (NCI). The demonstration had previously been limited to cancer treatment trials. The expansion, effective in June, was somewhat of a last-ditch effort to entice more TRICARE beneficiaries into the demonstration so that TRICARE could obtain more data on which to base future decisions. Between January 1996 and August 1998, only 155 TRICARE beneficiaries enrolled in NCI trials, and those were almost exclusively for bone marrow transplants.

Of course, TRICARE has a much better record on covering patient costs of participating in cancer clinical trials than almost any other health plan. Sens. Jay Rockefeller (D-W. Va.) and Connie Mack (R-Fla.) have been trying for years to persuade Congress to pass a bill authorizing a Medicare demonstration that would ensure coverage of patient care costs. No bill has ever gotten out of a Senate committee.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content